Reporting from: – American Society of Hematology 46th Annual Meeting, December 4-7, 2004, San Diego – San Antonio Breast Cancer Symposium, December 8-11, 2004 – Gastrointestinal Canc
Reporting from:
– American Society of Hematology 46th Annual Meeting, December 4-7, 2004, San Diego
– San Antonio Breast Cancer Symposium, December 8-11, 2004
– Gastrointestinal Cancers Symposium, January 27-29, 2005, Hollywood, Florida
In this edition:
Responses to a new drug, BMS 354 825, have been achieved among patients whose chronic myeloid leukemia has relapsed after treatment with
imatinib, said Charles Sawyers at the ASH conference. Early results with
another imatinib alternative, AMN 107, are also promising, as discussed by
Francis Giles.
The ATAC trial (Arimidex and Tamoxifen: Alone or in Combination), designed to find out whether it’s better to have five years of single-agent tamoxifen or single-agent anastrazole for breast cancer, now has 68 months of follow-up. Tony Howell presented data in San Antonio showing a superiority for aromatase inhibition in postmenopausal women.
The benefit of adding bevacizumab targeted therapy to cytotoxic regimens
among pretreated patients with advanced colorectal cancer was announced at the Gastrointestinal Cancers Symposium. Bruce Giantonio presented results from the Eastern Cooperative Oncology Group study in which bevacizumab was added to FOLFOX chemotherapy and produced an improvement in survival.
….
Related Episodes
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
María-Victoria Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings
This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.